← FDA DRUG APPROVALS

FDA ANDA · ANDA065041

DOXYCYCLINE

Sponsor: WATSON LABS

APPLICATION
ANDA065041
TYPE
ANDA
ORIGINAL APPROVAL
2000-04-28
LATEST ACTION
2002-07-24
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

DOXYCYCLINEDiscontinued
DOXYCYCLINE EQ 50MG BASE · CAPSULE · ORAL
DOXYCYCLINEDiscontinued
DOXYCYCLINE EQ 100MG BASE · CAPSULE · ORAL

Approval history

2002-07-24Manufacturing (CMC) · Supplement 12AP
2002-06-28Manufacturing (CMC) · Supplement 14AP
2002-02-20Labeling · Supplement 13AP
2002-02-08Manufacturing (CMC) · Supplement 10AP
2001-11-02Manufacturing (CMC) · Supplement 8AP
2001-09-24Manufacturing (CMC) · Supplement 9AP
2001-08-23Manufacturing (CMC) · Supplement 7AP
2000-12-18Manufacturing (CMC) · Supplement 6AP
2000-12-18Manufacturing (CMC) · Supplement 4AP
2000-12-18Manufacturing (CMC) · Supplement 5AP
2000-12-18Manufacturing (CMC) · Supplement 3AP
2000-11-14Manufacturing (CMC) · Supplement 1AP
2000-04-28OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →